1. Home
  2. VOXR vs FULC Comparison

VOXR vs FULC Comparison

Compare VOXR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

SELL

Current Price

$4.21

Market Cap

339.1M

ML Signal

SELL

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

SELL

Current Price

$3.73

Market Cap

281.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
VOXR
FULC
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
339.1M
281.1M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
VOXR
FULC
Price
$4.21
$3.73
Analyst Decision
Strong Buy
Hold
Analyst Count
7
5
Target Price
★ $7.67
$3.67
AVG Volume (30 Days)
526.9K
★ 1.2M
Earning Date
11-11-2026
11-12-2026
Dividend Yield
★ 1.37%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.99
$2.83
52 Week High
$6.70
$15.74

Technical Indicators

Market Signals
Indicator
VOXR
FULC
Relative Strength Index (RSI) 36.18 53.24
Support Level $4.13 $3.75
Resistance Level $5.16 $3.81
Average True Range (ATR) 0.20 0.07
MACD -0.03 0.01
Stochastic Oscillator 10.16 71.88

Price Performance

Historical Comparison
VOXR
FULC

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: